Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Histone deacetylase (HDAC) is one of the most characterized epigenetic modifiers, modulating chromatin structure and gene expression, which plays an important role in cell cycle, differentiation and apoptosis. Dysregulation of HDAC promotes cancer progression, thus inhibitors targeting HDACs have ev...

Full description

Bibliographic Details
Main Authors:	Yichen Sun, Jing Han Hong, Zhiqiang Ning, Desi Pan, Xin Fu, Xianping Lu, Jing Tan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Pharmacology
Subjects:	tucidinostat HDAC cancer immunotherapy lymphoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.932914/full

Similar Items

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
by: Hastono Ridwansyah, et al.
Published: (2023-09-01)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
by: Jinmei Zhou, et al.
Published: (2022-12-01)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
by: Xiaoguang Wang, et al.
Published: (2020-03-01)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
by: Edith Borcoman, et al.
Published: (2021-12-01)

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy
by: Nisha Holay, et al.
Published: (2023-09-01)

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
by: Anna Fontana, et al.
Published: (2022-09-01)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
by: Ehab Ghazy, et al.
Published: (2022-01-01)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
by: Christian Mayr, et al.
Published: (2021-07-01)

The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention
by: Rahma K. Alseksek, et al.
Published: (2022-07-01)

A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B‐cell lymphoma
by: Maria Joosten, et al.
Published: (2016-10-01)

HDAC-an important target for improving tumor radiotherapy resistance
by: Rui Ling, et al.
Published: (2023-07-01)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
by: Christian Schrenk, et al.
Published: (2023-03-01)

Microglial Expression of Hdac1 and Hdac2 is Dispensable for Experimental Autoimmune Encephalomyelitis (EAE) Progression
by: Moumita Datta, et al.
Published: (2020-10-01)

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
by: Yoichi Imai, et al.
Published: (2019-04-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
by: Hany S. Ibrahim, et al.
Published: (2021-12-01)

Pathological Role of HDAC8: Cancer and Beyond
by: Ji Yoon Kim, et al.
Published: (2022-10-01)

Methionine 274 Is Not the Determining Factor for Selective Inhibition of Histone Deacetylase 8 (HDAC8) by L-Shaped Inhibitors
by: Niklas Jänsch, et al.
Published: (2022-10-01)

Ring size changes in the development of class I HDAC inhibitors
by: Er-Chieh Cho, et al.
Published: (2021-01-01)

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
by: Chen Shen, et al.
Published: (2023-05-01)

Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors
by: Emre F. Bülbül, et al.
Published: (2022-04-01)

Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
by: Yuqian Wang, et al.
Published: (2023-09-01)

Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis
by: Lihua Dong, et al.
Published: (2021-01-01)

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
by: Filippo Spriano, et al.
Published: (2022-08-01)

HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
by: Dimitris Karagiannis, et al.
Published: (2021-07-01)

Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors
by: Omnia R. Elbatrawy, et al.
Published: (2023-07-01)

HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights
by: Eugenia Passaro, et al.
Published: (2021-12-01)

Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors
by: Nicolas Gillet, et al.
Published: (2012-10-01)

HDAC11, an emerging therapeutic target for metabolic disorders
by: Huizhen Chen, et al.
Published: (2022-10-01)

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
by: Giorgio Milazzo, et al.
Published: (2020-05-01)

The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells
by: Laura Urwanisch, et al.
Published: (2023-02-01)

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
by: Feng-Lung Tsai, et al.
Published: (2023-08-01)

Long non-coding RNA histone deacetylase 4 antisense RNA 1 (HDAC4-AS1) inhibits HDAC4 expression in human ARPE-19 cells with hypoxic stress
by: Jie Pan, et al.
Published: (2021-01-01)

DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro
by: Eliza Mari Kwesi-Maliepaard, et al.
Published: (2022-11-01)

HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation
by: Qian-qian Zhang, et al.
Published: (2023-07-01)

Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety
by: Al-Sanea MM, et al.
Published: (2020-02-01)

Discovery of Indole-Containing Benzamide Derivatives as HDAC1 Inhibitors with In Vitro and In Vivo Antitumor Activities
by: Xiu Gu, et al.
Published: (2022-06-01)

Targeting cancers and metabolic disorders: The prospects of combining HDAC8 inhibitor and activator
by: Mohammed Mukhtar Yusif
Published: (2023-04-01)

HDAC inhibitor attenuates rat traumatic brain injury induced neurological impairments
by: Yiming Lu, et al.
Published: (2023-08-01)

Therapeutic Efficacy of Novel HDAC Inhibitors SPA3052 and SPA3074 against Intestinal Inflammation in a Murine Model of Colitis
by: Ji-In Yoon, et al.
Published: (2022-12-01)